Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Irinotecan vs Oxaliplatin in Refractory mCRC
NCT03567629Phase 2Unknown
- Sponsor
- Peking University
- Start
- May 2018
- Primary completion
- Dec 2021
- Modality
- Nanoparticles, Monoclonal Antibodies, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of irinotecan hydrochloride liposome injection (II) + temozolomide + bevacizumab in colorectal cancer (metastatic) (mCRC), sponsored by Peking University. Status: unknown.
02
Drugs
irinotecan hydrochloride liposome injection (II) + temozolomide + bevacizumab
03
Conditions
colorectal cancer (metastatic) (mCRC)
Beyond the preview
Go deeper on NCT03567629.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03567629.